Covid-19

Flood Biotech began with a relatively simple question – can methodology that was used to successfully predict financial market movement be applied to genetics and vaccine development?

The result was 38 days of programming by our founder.

The result was initially just an overview of all genetic material in the NIH databases. But that led to the development of a genetic “primer” or key that could be used as a lens through which to view all genetic material.

Once that was in place the development of follow-on modules allowed for the rapid development of vaccine candidates. Vaccine candidates that could be built not in months or years, but in hours. And for single samples, seconds.

This is a highly unusual approach, and doesn’t follow the traditional lab-based vaccine and anti-bacterial development model.

Our model is entirely based on math.

Given the time frame of the spread of the Covid-19, and the realization that the Covid-19 is actually a species killer, there wasn’t any time to waste.

Once that work was complete, we realized that not only would the methodology work for Covid-19, but that it would work for nearly every disease for which a complete genetic sequence existed.

While the initial focus was on the Covid-19, several tests were run on other random viral and bacterial samples — with similar results.

Our technology allows us to rapidly identify complex structures and to use those structures in the creation of vaccine and anti-bacterial candidates.

To date we have two granted patents, and one near grant.

After Covid-19, our next major projects will be Malaria and Tuberculosis.